

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

Unknown
Unknown
01234567890ABCD, 012345
01234567890ABCD
00/00/0000 00:00

Glycogen Storage Disease, Type 1A (G6PC), 9 Variants ARUP test code 2013740					
Glycogen Storage Disease, Specimen	Whole Blood				
Glycogen Storage Disease, Allele 1	Negative				
Glycogen Storage Disease, Allele 2	Negative				
Glycogen Storage Disease, Interp	See Note Indication for testing: Carrier screening or diagnostic testing for glycogen storage disease type 1A.				
	Negative: This sample is negative for the 9 variants tested in the G6PC gene. If this is an asymptomatic individual of Ashkenazi Jewish descent, his/her risk of being a carrier of glycogen storage disease type 1A has been reduced from 1 in 71 to approximately 1 in 7,000. This result has been reviewed and approved by				

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2767 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



BACKGROUND INFORMATION: Glycogen Storage Disease, Type 1A (G6PC), 9 Variants
CHARACTERISTICS: Infants typically present at 3 to 4 months of age with hepatomegaly, lactic acidosis, hyperuricemia, hyperlipidemia, hypertriglyceridemia and/or hypoglycemic seizures. Other characteristics include growth delay leading to short stature, osteoporosis, delayed puberty, renal disease, and hepatic adenomas with potential for malignancy. With treatment, affected individuals often live into adulthood. INCIDENCE: 1 in 20,000 in Ashkenazi Jewish individuals. INHERITANCE: Autosomal recessive.
CAUSE: G6PC pathogenic variants.
VARIANTS TESTED: p.Q27Rfs (c.79delC), Y128Tfs (c.379_380dupTA), p.R83H (c.248G>A), p.R83C (c.247C>T), p.G188R (c.562G>C), p.Q242X (c.724C>T), p.Q347X (c.1039C>T), p.G270V (c.809G>T), p.F327del (c.979_981delTTC).
CLINICAL SENSITIVITY: 99 percent in Ashkenazi Jewish individuals; varies by ethnicity in non-Ashkenazi Jewish individuals.
METHODOLOGY: Polymerase chain reaction (PCR) and fluorescence monitoring.
ANALYTICAL SENSITIVITY AND SPECIFICITY: Greater than 99 percent. LIMITATIONS: Variants other than those tested will not be detected. Diagnostic errors can occur due to rare sequence variations.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Glycogen Storage Disease, Specimen	23-304-101683	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Glycogen Storage Disease, Allele 1	23-304-101683	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Glycogen Storage Disease, Allele 2	23-304-101683	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Glycogen Storage Disease, Interp	23-304-101683	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 23-304-101683 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 2 | Printed: 1/31/2024 3:20:04 PM 4848